This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4 Jul 2011

Merck Receives Approval to Market Three Products In Japan

Merck's three pharma products have been approved for the Japanese market.

Merck announced last week that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved three pharma products - GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], ZOLINZA (vorinostat) and CUBICIN (daptomycin for injection) – for use in Japan.


In Japan, GARDASIL, a quadrivalent human papillomavirus (HPV) vaccine, was approved for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) and their precursor lesions (cervical intraepithelial neoplasm grade 1/2/3 and cervical adenocarcinoma in situ), vulvar intraepithelial neoplasia grade 1/2/3, vaginal intraepithelial neoplasia grade 1/2/3 and genital warts caused by HPV types 6, 11, 16 and 18 in females 9 years of age and older.


Related News